These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21080734)

  • 1. The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments.
    Manca A; Sculpher MJ; Goeree R
    Pharmacoeconomics; 2010; 28(12):1079-96. PubMed ID: 21080734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modeling.
    Manca A; Lambert PC; Sculpher M; Rice N
    Med Decis Making; 2007; 27(4):471-90. PubMed ID: 17641141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generalisability in economic evaluation studies in healthcare: a review and case studies.
    Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
    Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian modelling of healthcare resource use in multinational randomized clinical trials.
    Gauthier A; Manca A; Anton S
    Pharmacoeconomics; 2009; 27(12):1017-29. PubMed ID: 19908926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The multinational nature of cost-effectiveness analyses alongside multinational clinical trials.
    Rivero-Arias O; Gray A
    Value Health; 2010; 13(1):34-41. PubMed ID: 20667068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of costs and cost-effectiveness in multinational trials.
    Koopmanschap MA; Touw KC; Rutten FF
    Health Policy; 2001 Nov; 58(2):175-86. PubMed ID: 11551665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models.
    Manca A; Rice N; Sculpher MJ; Briggs AH
    Health Econ; 2005 May; 14(5):471-85. PubMed ID: 15386662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Globally optimal trial design for local decision making.
    Eckermann S; Willan AR
    Health Econ; 2009 Feb; 18(2):203-16. PubMed ID: 18435429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The road not taken: transferability issues in multinational trials.
    Vemer P; Rutten-van Mölken MP
    Pharmacoeconomics; 2013 Oct; 31(10):863-76. PubMed ID: 23979963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus.
    Reed SD; Anstrom KJ; Bakhai A; Briggs AH; Califf RM; Cohen DJ; Drummond MF; Glick HA; Gnanasakthy A; Hlatky MA; O'Brien BJ; Torti FM; Tsiatis AA; Willan AR; Mark DB; Schulman KA
    Am Heart J; 2005 Mar; 149(3):434-43. PubMed ID: 15864231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
    Williams I; McIver S; Moore D; Bryan S
    Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
    Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
    Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methodological developments in randomized controlled trial-based economic evaluations.
    Thorn JC; Noble SM; Hollingworth W
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):843-56. PubMed ID: 25179207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analytic considerations in economic evaluations of multinational cardiovascular clinical trials.
    Torti FM; Reed SD; Schulman KA
    Value Health; 2006; 9(5):281-91. PubMed ID: 16961546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collecting and analysing cost data for complex public health trials: reflections on practice.
    Batura N; Pulkki-Brännström AM; Agrawal P; Bagra A; Haghparast-Bidgoli H; Bozzani F; Colbourn T; Greco G; Hossain T; Sinha R; Thapa B; Skordis-Worrall J
    Glob Health Action; 2014; 7():23257. PubMed ID: 24565214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating country-specific cost-effectiveness from multinational clinical trials.
    Willke RJ; Glick HA; Polsky D; Schulman K
    Health Econ; 1998 Sep; 7(6):481-93. PubMed ID: 9809707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the appropriateness of combining economic data from multinational clinical trials.
    Cook JR; Drummond M; Glick H; Heyse JF
    Stat Med; 2003 Jun; 22(12):1955-76. PubMed ID: 12802815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of a multinational RCT with a binary measure of effectiveness and an interacting covariate.
    Willan AR; Kowgier ME
    Health Econ; 2008 Jul; 17(7):777-91. PubMed ID: 17764096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.